KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Accounts Payables: 2010-2025

Historic Accounts Payables for Halozyme Therapeutics (HALO) over the last 17 years, with Sep 2025 value amounting to $15.4 million.

  • Halozyme Therapeutics' Accounts Payables rose 23.89% to $15.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.4 million, marking a year-over-year increase of 23.89%. This contributed to the annual value of $10.2 million for FY2024, which is 13.26% down from last year.
  • Per Halozyme Therapeutics' latest filing, its Accounts Payables stood at $15.4 million for Q3 2025, which was down 17.82% from $18.7 million recorded in Q2 2025.
  • Halozyme Therapeutics' 5-year Accounts Payables high stood at $20.1 million for Q1 2025, and its period low was $535,000 during Q1 2021.
  • Its 3-year average for Accounts Payables is $14.1 million, with a median of $13.3 million in 2024.
  • Per our database at Business Quant, Halozyme Therapeutics' Accounts Payables crashed by 93.57% in 2021 and then skyrocketed by 1,048.15% in 2022.
  • Quarterly analysis of 5 years shows Halozyme Therapeutics' Accounts Payables stood at $1.5 million in 2021, then skyrocketed by 1,048.15% to $17.7 million in 2022, then crashed by 33.22% to $11.8 million in 2023, then decreased by 13.26% to $10.2 million in 2024, then grew by 23.89% to $15.4 million in 2025.
  • Its Accounts Payables stands at $15.4 million for Q3 2025, versus $18.7 million for Q2 2025 and $20.1 million for Q1 2025.